Monograph Capital Partners
SelectiveFiled to raiseWilmington, DEBiotechnology, Healthcare, ManufacturingLast fund filed March 2024
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Monograph Capital Partners II | March 2024 | Indefinite | $154M | 48 |
| Monograph Capital Partners IFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Fred Cohen | Selective | Biotech & pharma, Digital health, Gaming & entertainment | 13 |
Classified sectors of Monograph Capital Partners’s own portfolio companies, based on 13 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Monograph Capital Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Vida Ventures | 13 | ASCEND ADVANCED THERAPIES GROUP, Ascend Gene & Cell Therapies, Asklepios BioPharmaceutical, Auxogyn, CareDx, Cell Design Labs, Chicken Soup for the Soul Entertainment, Firefly Neuroscience, Kyverna Therapeutics, Ollin Biosciences, RAPID MICRO BIOSYSTEMS, Roka BioScience, VERACYTE |
| Kleiner Perkins | 2 | Auxogyn, Cell Design Labs |
| Versant Venture Capital | 2 | Cell Design Labs, VERACYTE |
| 2 |
| Charles Conn | Quiet | None listed | 1 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Westlake Biopartners | 2 | Auxogyn, Cell Design Labs |
| ARCH Venture Partners | 1 | Ollin Biosciences |
| Bain Capital Life Sciences | 1 | RAPID MICRO BIOSYSTEMS |
| Caduceus Capital | 1 | Roka BioScience |
| KSN | 1 | CareDx |
| Orbimed Genesis | 1 | Roka BioScience |
A shared board seat: a company where filings name a Monograph Capital Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.